OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.
paper
Cited
Public
- Authors
- Mague, Stephen D; Blendy, Julie A
- Year
- 2010
- Journal
- Drug and alcohol dependence
- PMID
- 20074870
- DOI
- 10.1016/j.drugalcdep.2009.12.016
- PMCID
- PMC2887703
Endogenous opioids acting at mu-opioid receptors mediate many biological functions. Pharmacological intervention at these receptors has greatly aided in the treatment of acute and chronic pain, in addition to other uses. However, the development of tolerance and dependence has made it difficult to adequately prescribe these therapeutics. A common single nucleotide polymorphism (SNP), A118G, in the mu-opioid receptor gene can affect opioid function and, consequently, has been suggested to contribute to individual variability in pain management and drug addiction. Investigation into the role of A118G in human disease and treatment response has generated a large number of association studies across various disease states as well as physiological responses. However, characterizing the functional consequences of this SNP and establishing if it causes or contributes to disease phenotypes have been significant challenges. In this manuscript, we will review a number of association studies as well as investigations of the functional impact of this gene variant. In addition, we will describe a novel mouse model that was generated to recapitulate this SNP in mice. Evaluation of models that incorporate known human genetic variants into a tractable system, like the mouse, will facilitate the understanding of discrete contributions of SNPs to human disease.
No figures extracted from this document.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A multiscale atlas of Oprm1-expressing neurons in the central nervous system: Brain-wide distribution, circuit functions, and translational therapeutic implications. | Zhang Z et al. | β | 2025 | β |
| De novo post-COVID-19 chronic pain: a piece of information about risk factor and clinical features. | Goncalves FT et al. | β | 2025 | β |
| Similarities and Differences in Genetics. | Liu W et al. | β | 2025 | β |
| Anxious-depressive attack and rejection sensitivity-Toward a new approach to treatment-resistant depression. | Kaiya H | β | 2024 | β |
| Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessment. | Dunn KE et al. | β | 2024 | β |
| 5. Collaborative Study on the Genetics of Alcoholism: Functional genomics. | Gameiro-Ros I et al. | β | 2023 | β |
| Association of Mu opioid receptor (A118G) and BDNF (G196A) polymorphisms with rehabilitation-induced cortical inhibition and analgesic response in chronic osteoarthritis pain. | GonΓ§alves FT et al. | β | 2023 | β |
| Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol. | Karoly HC et al. | β | 2023 | β |
| Drug testing in support of the diagnosis of neonatal abstinence syndrome: The current situation. | Langman LJ et al. | β | 2023 | β |
| Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression. | Baldo BA | β | 2023 | β |
| Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. | Ceccanti M et al. | β | 2022 | β |
| A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. | Chawar C et al. | β | 2021 | β |
| Effects of Voluntary Running Wheel Exercise-Induced Extracellular Vesicles on Anxiety. | Yoon KJ et al. | β | 2021 | β |
| Increased functional coupling of the mu opioid receptor in the anterior insula of depressed individuals. | Lutz PE et al. | β | 2021 | β |
| Overview of Genetic Analysis of Human Opioid Receptors. | Spampinato SM | β | 2021 | β |
| Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis. | Levran O et al. | β | 2021 | β |
| Prenatal opioid exposure and vulnerability to future substance use disorders in offspring. | Abu Y et al. | β | 2021 | β |
| Role of toll-like receptor 4 antagonist Lipopolysaccharide-Rhodobacter sphaeroides on acute stress-induced voluntary ethanol preference and drinking behaviour: In vivo Swiss Albino mouse model. | Chuang HG et al. | β | 2021 | β |
| The Laboratory of the Biology of Addictive Diseases: Four Women in Neuroscience. | Kreek MJ et al. | β | 2021 | β |
| Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. | Halikere A et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Neurobehavioral effects of neonatal opioid exposure in mice: Influence of the OPRM1 SNP. | Robinson SA et al. | β | 2020 | β |
| Opioid Receptor ΞΌ-1 and Ketamine Effects in a Suicidal Depression Trial: A Post Hoc Exploration. | Grunebaum MF et al. | β | 2020 | β |
| OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. | Hendershot CS et al. | β | 2020 | β |
| Prenatal Opioid Exposure Enhances Responsiveness to Future Drug Reward and Alters Sensitivity to Pain: A Review of Preclinical Models and Contributing Mechanisms. | Grecco GG et al. | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| The opioid system and the social brain: implications for depression and suicide. | Lutz PE et al. | β | 2020 | β |
| The Role of Opiates in Social Pain and Suicidal Behavior. | Nobile B et al. | β | 2020 | β |
| The ΞΌ-opioid receptor gene A118G polymorphism is associated with insecure attachment in children with disruptive mood regulation disorder and their mothers. | Cimino S et al. | β | 2020 | β |
| Allele-Specific Methylation of SPDEF: A Novel Moderator of Psychosocial Stress and Substance Abuse. | Tay N et al. | β | 2019 | β |
| Associations among the opioid receptor gene (<i>OPRM1</i>) A118G polymorphism, psychiatric symptoms, and quantitative EEG in Korean males with gambling disorder: A pilot study. | Kim KM et al. | β | 2019 | β |
| Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse. | Gendy MNS et al. | β | 2019 | β |
| <i>OPRM1</i> A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches. | Taqi MM et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry. | Popova D et al. | β | 2019 | β |
| A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity. | Schuckit MA | β | 2018 | β |
| Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons | Halikere A et al. | β | 2018 | β |
| Focusing on the Opioid System for Addiction Biomarker Discovery. | Belzeaux R et al. | β | 2018 | β |
| Opioids: The Painful Public Health Reality. | Tyndale RF et al. | β | 2018 | β |
| Parental overcontrol x OPRM1 genotype interaction predicts school-aged children's sympathetic nervous system activation in response to performance challenge. | Partington LC et al. | β | 2018 | β |
| A cis-eQTL in OPRM1 is Associated with Subjective Response to Alcohol and Alcohol Use. | Otto JM et al. | β | 2017 | β |
| A prospective study of genetic factors, human laboratory phenotypes, and heavy drinking in late adolescence. | Hendershot CS et al. | β | 2017 | β |
| Onset of labour epidural analgesia with low-dose bupivacaine and different doses of fentanyl. | Vedagiri Sai R et al. | β | 2017 | β |
| The ΞΌ-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. | Levran O et al. | β | 2017 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. | Hendershot CS et al. | β | 2016 | β |
| Common Polymorphisms in the Age of Research Domain Criteria (RDoC): Integration and Translation. | Glatt CE et al. | β | 2016 | β |
| Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. | Kraft WK et al. | β | 2016 | β |
| Sweet taste pleasantness is modulated by morphine and naltrexone. | Eikemo M et al. | β | 2016 | β |
| To quit or not: Vulnerability of women to smoking tobacco. | Park SJ et al. | β | 2016 | β |
| A6V polymorphism of the human ΞΌ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro. | Knapman A et al. | β | 2015 | β |
| Association between Opioid Receptor mu 1 (OPRM1) Gene Polymorphisms and Tobacco and Alcohol Consumption in a Spanish Population. | FrancΓ¨s F et al. | β | 2015 | β |
| Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human ΞΌ-opioid receptor (OPRM1). | Knapman A et al. | β | 2015 | β |
| Challenges for opioid receptor nomenclature: IUPHAR Review 9. | Cox BM et al. | β | 2015 | β |
| Detection of mu opioid receptor (MOPR) and its glycosylation in rat and mouse brains by western blot with anti-ΞΌC, an affinity-purified polyclonal anti-MOPR antibody. | Huang P et al. | β | 2015 | β |
| Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. | PeciΓ±a M et al. | β | 2015 | β |
| Endogenous opioids: opposing stress with a cost. | Valentino RJ et al. | β | 2015 | β |
| Endogenous Opioids: The Downside of Opposing Stress. | Valentino RJ et al. | β | 2015 | β |
| Morphine-induced internalization of the L83I mutant of the rat ΞΌ-opioid receptor. | Cooke AE et al. | β | 2015 | β |
| Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. | Mague SD et al. | β | 2015 | β |
| Mouse model of OPRM1 (A118G) polymorphism increases sociability and dominance and confers resilience to social defeat. | Briand LA et al. | β | 2015 | β |
| Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-administration behavior compared with wild-type mice. | Zhang Y et al. | β | 2015 | β |
| Opioids in pregnancy and neonatal abstinence syndrome. | Stover MW et al. | β | 2015 | β |
| Variations in opioid receptor genes in neonatal abstinence syndrome. | Wachman EM et al. | β | 2015 | β |
| Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPΞ³S binding in mice with Oprm1 A112G. | Wang YJ et al. | β | 2014 | β |
| Buprenorphine signalling is compromised at the N40D polymorphism of the human ΞΌ opioid receptor in vitro. | Knapman A et al. | β | 2014 | β |
| Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. | Cargnin S et al. | β | 2014 | β |
| Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. | Hendershot CS | β | 2014 | β |
| Pharmacokinetic-pharmacodynamic modelling of the analgesic and antihyperalgesic effects of morphine after intravenous infusion in human volunteers. | Ravn P et al. | β | 2014 | β |
| Subjective health complaints in patients with lumbar radicular pain and disc herniation are associated with a sex - OPRM1 A118G polymorphism interaction: a prospective 1-year observational study. | Hasvik E et al. | β | 2014 | β |
| Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. | Cooper AJ et al. | β | 2013 | β |
| Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. | Levran O et al. | β | 2013 | β |
| Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. | Wachman EM et al. | β | 2013 | β |
| ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers. | Daws SE et al. | β | 2013 | β |
| Endogenous morphine and its metabolites in mammals: history, synthesis, localization and perspectives. | Laux-Biehlmann A et al. | β | 2013 | β |
| Functional characteristics of the naked mole rat ΞΌ-opioid receptor. | Busch-Dienstfertig M et al. | β | 2013 | β |
| Genotyping the Mu-opioid receptor A118G polymorphism using the real-time amplification refractory mutation system: allele frequency distribution among Brazilians. | Daher M et al. | β | 2013 | β |
| Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients. | Marini V et al. | β | 2013 | β |
| Is the rodent maternal separation model a valid and effective model for studies on the early-life impact on ethanol consumption? | Nylander I et al. | β | 2013 | β |
| Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. | Falcone M et al. | β | 2013 | β |
| Opioid receptors: distinct roles in mood disorders. | Lutz PE et al. | β | 2013 | β |
| Opioid system genes in alcoholism: a case-control study in Croatian population. | Cupic B et al. | β | 2013 | β |
| OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study. | Chen YT et al. | β | 2013 | β |
| Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. | Hajj A et al. | β | 2013 | β |
| Recent developments in the study of opioid receptors. | Cox BM | β | 2013 | β |
| The multiple facets of opioid receptor function: implications for addiction. | Lutz PE et al. | β | 2013 | β |
| ΞΌ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption. | Rouvinen-LagerstrΓΆm N et al. | β | 2013 | β |
| A common single nucleotide polymorphism A118G of theΒ ΞΌ opioid receptor alters its N-glycosylation and protein stability. | Huang P et al. | β | 2012 | β |
| A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. | Verhagen M et al. | β | 2012 | β |
| Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. | Mannelli P et al. | β | 2012 | β |
| COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. | Heinzerling KG et al. | β | 2012 | β |
| Ethnic-specific meta-analyses of association between the OPRM1 A118G polymorphism and alcohol dependence among Asians and Caucasians. | Chen D et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice. | Cinque C et al. | β | 2012 | β |
| Neuropeptides as mediators of the early-life impact on the brain; implications for alcohol use disorders. | Nylander I et al. | β | 2012 | β |
| Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. | Kreek MJ et al. | β | 2012 | β |
| Reduced expression of the ΞΌ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. | Wang YJ et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The human ΞΌ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. | Menon S et al. | β | 2012 | β |
| The promise of pharmacogenetics in labor analgesiaβ¦tantalizing, but not there yet. | Wong CA | β | 2012 | β |
| Translational genetic approaches to substance use disorders: bridging the gap between mice and humans. | Palmer AA et al. | β | 2012 | β |
| Utility of genetically modified mice for understanding the neurobiology of substance use disorders. | Fowler CD et al. | β | 2012 | β |
| ΞΌ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. | Falcone M et al. | β | 2012 | β |
| Functional polymorphism of the mu-opioid receptor gene (OPRM1) influences reinforcement learning in humans. | Lee MR et al. | β | 2011 | β |
| Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. | Ray R et al. | β | 2011 | β |
| Individual differences in morphine and butorphanol analgesia: a laboratory pain study. | Sibille KT et al. | β | 2011 | β |
| Pharmacological consequence of the A118G ΞΌ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of CaΒ²βΊ channels in humanized mouse sensory neurons. | Mahmoud S et al. | β | 2011 | β |
| The response to naltrexone in ethanol-drinking rats depends on early environmental experiences. | Daoura L et al. | β | 2011 | β |
| Individualised treatment in alcohol-dependent patients. | Mann K et al. | β | 2010 | β |
| Introduction to the College on Problems of Drug Dependence special issue: contemporary advances in opioid neuropharmacology. | Walsh SL et al. | β | 2010 | β |
| Overview and historical perspective of four papers presented on research related to the endogenous opioid system. | Kreek MJ | β | 2010 | β |